Ashley Pharmatech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 20-12-2024
- Paid Up Capital ₹ 0.10 M
as on 20-12-2024
- Company Age 14 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.55 Cr
as on 20-12-2024
- Revenue -6.56%
(FY 2023)
- Profit 0.12%
(FY 2023)
- Ebitda -12.03%
(FY 2023)
- Net Worth 14.70%
(FY 2023)
- Total Assets 0.80%
(FY 2023)
About Ashley Pharmatech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.55 Cr.
Aryan Agarwal and Neeraj Agarwal serve as directors at the Company.
- CIN/LLPIN
U24230DL2010PTC202596
- Company No.
202596
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 May 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Ashley Pharmatech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aryan Agarwal  | Director | 05-Mar-2022 | Current |
| Neeraj Agarwal | Director | 06-Jun-2015 | Current |
Financial Performance of Ashley Pharmatech.
Ashley Pharmatech Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 6.56% decrease. The company also saw a slight improvement in profitability, with a 0.12% increase in profit. The company's net worth Soared by an impressive increase of 14.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ashley Pharmatech?
In 2023, Ashley Pharmatech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Panacea Orgichem Private LimitedActive 3 years 3 monthsAryan Agarwal and Neeraj Agarwal are mutual person
- Elder Orgichem Private LimitedActive 3 years 3 months
Aryan Agarwal and Neeraj Agarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 29 Oct 2024 | ₹1.10 M | Open |
Canara Bank Creation Date: 03 Sep 2021 | ₹1.50 Cr | Open |
Axis Bank Limited Creation Date: 20 Mar 2021 | ₹5.50 M | Open |
How Many Employees Work at Ashley Pharmatech?
Unlock and access historical data on people associated with Ashley Pharmatech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ashley Pharmatech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ashley Pharmatech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
